| pubmed-article:12181041 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12181041 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:12181041 | lifeskim:mentions | umls-concept:C0001675 | lld:lifeskim |
| pubmed-article:12181041 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:12181041 | lifeskim:mentions | umls-concept:C0023449 | lld:lifeskim |
| pubmed-article:12181041 | lifeskim:mentions | umls-concept:C0010711 | lld:lifeskim |
| pubmed-article:12181041 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:12181041 | pubmed:dateCreated | 2002-8-15 | lld:pubmed |
| pubmed-article:12181041 | pubmed:abstractText | In this national study, we have evaluated a new intensive chemotherapy protocol for adult patients with untreated acute lymphoblastic leukaemia (ALL). One hundred and fifty-three patients with median age 42 years received induction therapy with high-dose cytarabine (Ara-C), cyclophosphamide, daunorubicin, vincristine and betamethasone. A high complete remission (CR) rate (90%) was achieved in patients < 60 years compared with 70% in patients > 60 years (P = 0.004). The estimated 3 year overall survival for all patients was 29% (CI 21-36%) and the estimated continuous complete remission (CCR) at 3 years for the patients achieving CR according to the protocol was 36% (CI 27-45%). A favourable pretreatment characteristic was pre-B phenotype, especially for patients < 40 years without any high-risk factor, with an estimated CCR at 3 years of 62% (CI 41-82%). Stem cell transplantation (SCT) as post-remission therapy, mainly for high-risk patients, gave an estimated 3 year disease free survival (DFS) after SCT of 39% (CI 24-54%). No significant differences in DFS could be found between autologous, related or unrelated donor transplantation. We conclude that this intensive protocol resulted in a high CR rate combined with acceptable side-effects and a favourable CCR for patients with pre-B ALL. | lld:pubmed |
| pubmed-article:12181041 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12181041 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12181041 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12181041 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12181041 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12181041 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:12181041 | pubmed:issn | 0007-1048 | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:KarlssonKarin... | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:KimbyEvaE | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:TidefeltUlfU | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:BjörkholmMagn... | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:WahlinAndersA | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:StenkeLeifL | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:LöfvenbergEva... | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:PaulChristerC | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:HastRobertR | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:GrimforsGunna... | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:HallböökHelen... | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:SimonssonBeng... | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:AhlgrenThomas... | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:CarneskogJanJ | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:LernerRichard... | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:LinderOlleO | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:LinderholmMat... | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:MalmClaesC | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:NilssonPer-Gu... | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:StockelbergDi... | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:TuressonIngem... | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:Uden-BlomeAnn... | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:VilenLarsL | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:WinquistIngem... | lld:pubmed |
| pubmed-article:12181041 | pubmed:author | pubmed-author:SmedmyrBengtB | lld:pubmed |
| pubmed-article:12181041 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12181041 | pubmed:volume | 118 | lld:pubmed |
| pubmed-article:12181041 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12181041 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12181041 | pubmed:pagination | 748-54 | lld:pubmed |
| pubmed-article:12181041 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:12181041 | pubmed:meshHeading | pubmed-meshheading:12181041... | lld:pubmed |
| pubmed-article:12181041 | pubmed:meshHeading | pubmed-meshheading:12181041... | lld:pubmed |
| pubmed-article:12181041 | pubmed:meshHeading | pubmed-meshheading:12181041... | lld:pubmed |
| pubmed-article:12181041 | pubmed:meshHeading | pubmed-meshheading:12181041... | lld:pubmed |
| pubmed-article:12181041 | pubmed:meshHeading | pubmed-meshheading:12181041... | lld:pubmed |
| pubmed-article:12181041 | pubmed:meshHeading | pubmed-meshheading:12181041... | lld:pubmed |
| pubmed-article:12181041 | pubmed:meshHeading | pubmed-meshheading:12181041... | lld:pubmed |
| pubmed-article:12181041 | pubmed:meshHeading | pubmed-meshheading:12181041... | lld:pubmed |
| pubmed-article:12181041 | pubmed:meshHeading | pubmed-meshheading:12181041... | lld:pubmed |
| pubmed-article:12181041 | pubmed:meshHeading | pubmed-meshheading:12181041... | lld:pubmed |
| pubmed-article:12181041 | pubmed:meshHeading | pubmed-meshheading:12181041... | lld:pubmed |
| pubmed-article:12181041 | pubmed:meshHeading | pubmed-meshheading:12181041... | lld:pubmed |
| pubmed-article:12181041 | pubmed:meshHeading | pubmed-meshheading:12181041... | lld:pubmed |
| pubmed-article:12181041 | pubmed:meshHeading | pubmed-meshheading:12181041... | lld:pubmed |
| pubmed-article:12181041 | pubmed:meshHeading | pubmed-meshheading:12181041... | lld:pubmed |
| pubmed-article:12181041 | pubmed:meshHeading | pubmed-meshheading:12181041... | lld:pubmed |
| pubmed-article:12181041 | pubmed:meshHeading | pubmed-meshheading:12181041... | lld:pubmed |
| pubmed-article:12181041 | pubmed:meshHeading | pubmed-meshheading:12181041... | lld:pubmed |
| pubmed-article:12181041 | pubmed:meshHeading | pubmed-meshheading:12181041... | lld:pubmed |
| pubmed-article:12181041 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12181041 | pubmed:articleTitle | High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia. | lld:pubmed |
| pubmed-article:12181041 | pubmed:affiliation | The Swedish Adult ALL Group, Uppsala University Hospital, Sweden. helene.hallbook@medicin.uas.lul.se | lld:pubmed |
| pubmed-article:12181041 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12181041 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12181041 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12181041 | lld:pubmed |
